The first 1 monthly non-hormonal contraceptive product is expected to interview
ADC评论
October 12, 2022
On October 10, Daré Bioscience announced that the FDA granted an Investigational Device Exemption (IDE) application allowing it to conduct a pivotal Phase III clinical
